#USA #San Diego #Robbins LLP #SEC Fraud #Unicycive Therapeutics

Class Action Alert for Unicycive Therapeutics Investors

Robbins LLP, a firm specializing in shareholder rights, is actively urging stockholders of Unicycive Therapeutics, Inc. (symbol: UNCY) to consider participation in a recently filed class action lawsuit. This action was initiated on behalf of investors who purchased securities of Unicycive between March 29, 2024, and June 27, 2025. The lawsuit seeks to address significant financial losses experienced by shareholders following alarming disclosures related to the company’s drug development processes.

Context of the Class Action

Unicycive Therapeutics is a clinical-stage biotechnology company focusing on innovative therapies for medical conditions unmet in the U.S. market. The class action centers around allegations that Unicycive misrepresented the status of its New Drug Application (NDA) concerning oxylanthanum carbonate, aimed at treating hyperphosphatemia in chronic kidney disease patients undergoing dialysis.

Throughout the period leading up to the class action, Unicycive made assurances to investors regarding their readiness to meet compliance standards set by the U.S. Food and Drug Administration (FDA). However, the complaint contends that the company overstated both its capabilities and readiness which ultimately misled its investors.

The Allegations

Key among the allegations is the failure to disclose significant deficiencies identified by the FDA during its inspections of a third-party manufacturing vendor. On June 10, 2025, Unicycive publicly revealed that the FDA had flagged compliance issues related to good manufacturing practices (cGMP) at its manufacturing subcontractor. This revelation precipitated a dramatic drop of over 40% in Unicycive's stock price.

Further compounding the situation, a Complete Response Letter issued by the FDA on June 30, 2025, regarding the NDA for oxylanthanum carbonate noted these ongoing cGMP compliance issues. This communication resulted in an additional near 30% stock price decline, leaving many investors feeling the impact of these developments sharply.

What Affected Shareholders Can Do

If you believe you have been financially harmed due to your investment in Unicycive Therapeutics, Robbins LLP encourages you to reach out to them. The firm is not only interested in helping investo share their story but also in facilitating your potential role as a lead plaintiff if you wish to become an active participant in the class action.

It's vital to be aware of the deadlines, as any interested parties must express their desire to lead the case by October 14, 2025. However, participating in the class action is not a prerequisite for recovering losses — investors who choose not to get involved can still be classified as passive members of the group.

Robbins LLP operates on a contingency fee model, meaning that analyses and representation will incur no costs to the investors unless a positive resolution is achieved.

About Robbins LLP

Since its establishment in 2002, Robbins LLP has emerged as a noted advocate for shareholder rights, providing legal counsel to recover losses and improve corporate governance. The firm is committed to holding corporate executives accountable to their shareholders, thereby boosting investor confidence and integrity within the market. As the Unicycive case unfolds, shareholders can stay informed about potential outcomes and updates by subscribing to Stock Watch, a free alert service offered by Robbins LLP.

For more information or to get involved, shareholders can contact attorney Aaron Dumas, Jr. directly at Robbins LLP or visit their website to fill out a form. Legal representation could ensure that investors are equipped to seek restitution for their losses, highlighting the importance of action in times of corporate misconduct.

• ---